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The Regulation of Human Germline Genome 
Modification (HGGM) at the National Level: 
A Call for Comprehensive Legal Reform 
BY ANDREA BOGGIO, CESARE P.R. ROMANO, AND JESSICA ALMQVIST* 
INTRODUCTION 
The regulation of human germline genome modification (HGGM) 
had already been debated for at least a decade when Chinese doctor He 
Jianku dazed the world in December 2018 after announcing the birth of 
twins who had been genetically modified at the embryonic stage. How-
ever, He Jianku’s announcement turned the question from a theoretical 
problem into an actual one, forcing international and national decision 
makers to pay more attention to the regulation of HGGM both at the na-
tional and international levels. Some states regulate HGGM using legal 
instruments that date back to the 1990s or early mid-2000s, long before 
the advent of CRISPR made genetic editing considerably easier and 
cheaper. 
It is necessary to better understand how HGGM is regulated at the 
national level. Scientists need this understanding if they are to act respon-
sibly and be confident that they are on the right side of the law. Addition-
ally, better national regulatory frameworks are also necessary to achieve 
the creation of an international regulatory regime. As the World Health 
Organization’s Expert Advisory Committee on Developing Global 
Standards for Governance and Oversight of Human Genome Editing 
points out, national regulations are essential in the development of inter-
national and transnational governance of human genome editing because 
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governance is comprised of “a web of separate initiatives,” including in-
itiatives led by national lawmakers and regulators.1 
During the past three years, we carried out a comparative study of 
national regulatory frameworks of HGGM, and published the results in a 
volume entitled “Human Germline Modification and the Right to Sci-
ence: A Comparative Study of National Laws and Policies.”2 We invited 
experts in 18 states around the world to write essays discussing at great 
length how HGGM is regulated in their state.3 We also included an essay 
discussing the regulation of HGGM in Europe (European Union and 
Council of Europe), as well as on the global level. We published exten-
sive, critical analyses of these regulatory frameworks in light of the pre-
existing international human rights obligations of individual states. In 
particular, we focused on the so-called “right to science” (or, less suc-
cinctly, the right to benefit from progress in science and technology), as 
well as the rights of scientists and those that protect scientific research 
(the so-called “rights of science”). At the global level, these rights are 
codified in the Universal Declaration of Human Rights4 and the Interna-
tional Covenant on Economic, Social and Cultural Rights,5 and at the re-
gional level, they are set out in numerous legal instruments.6 We will not 
repeat these analyses here. Instead, this article further elaborates on the 
data presented in the essays in the book to facilitate comparison across 
national borders. For each state discussed in the book, we highlight fun-
damental statutory and administrative regulations and substantive provi-
sions pertaining to germline modifications. We show that national legal 
frameworks are fragmented and outdated, and thus inadequate. We con-
clude by identifying steps that states can take to clarify and modernize 
their regulatory frameworks. 
 
 1. A DRAFT Governance Framework for Human Genome Editing, WORLD HEALTH 
ORGANIZATION [WHO] (2020), https://www.who.int/ethics/topics/human-genome-editing/Gov-
ernance-framework-for-HGE-Jan2020.pdf. 
 2. ANDREA BOGGIO ET AL., HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT 
TO SCIENCE: A COMPARATIVE STUDY OF NATIONAL LAWS AND POLICIES (Andrea Boggio, Cesare 
P.R. Romano & Jessica Almqvist eds., 2020) [hereinafter HUMAN GERMLINE GENOME 
MODIFICATION AND THE RIGHT TO SCIENCE]. 
 3. Australia, Belgium, Canada, China, France, Germany, Israel, Italy, Japan, Mexico, Neth-
erlands, Singapore, South Korea, Spain, Sweden, Switzerland, the United Kingdom, and the United 
States. Id. at 17. 
 4. G.A. Res. 217 (III) A, Universal Declaration of Human Rights, art. 27 (Dec. 10, 1948). 
 5. International Covenant on Economic, Social and Cultural Rights art. 15, opened for sig-
nature Dec. 16, 1966, 993 U.N.T.S. 3 (entered into force Jan. 3, 1976). 
 6. For a discussion of these instruments, see Andrea Boggio et al., The Human Right to Sci-
ence and the Regulation of Human Germline Engineering, 2 CRISPR J. 134, 136 (2019); HUMAN 
GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE, supra note 2. 
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I. METHODOLOGY 
This article is based on data appearing in various chapters of “Hu-
man Germline Genome Modification and the Right to Science: A Com-
parative Study of National Laws and Policies.” The chapters were written 
by experts, following a template that we developed and handed out at the 
time the invited experts confirmed their interest in contributing to the pro-
ject. The template was prepared and distributed to ensure consistency 
among the various chapters. Among other things, the template asked them 
to discuss two items: (1) which legal sources regulate the subject matter 
(i.e., constitutional provisions, statutory law, administrative rules, regu-
lations, and guidelines), and (2) what those legal sources say about the 
subject matter, that is, to analyze the substantive provisions expressed by 
the national regulatory frameworks. The regulation of germline modifi-
cation was broken down into four steps, corresponding to different stages 
of the “bench to the bedside” research pipeline: basic research, preclinical 
research or research with animals, clinical research, and clinical applica-
tion.7 We refer to these stages as “subareas.” 
The analysis presented in this article focuses on some key legal 
questions: 
For basic research: whether the law defines gametes and 
embryos; whether research on gametes and embryos (both by 
creating research embryos and using IVF embryos) is permissi-
ble; and whether scientists can modify the genome of gametes 
and embryos used in research. 
For clinical research: whether modified germline tissue can 
be tested on humans; and how the law classifies these studies. 
For clinical applications: whether gene therapy or other in-
terventions based on germline modifications can be offered to 
patients, and if so, under what conditions. 
In this article, we do not discuss supranational legal instruments. 
However, several synapses refer to the two that are most relevant to 
HGGM: The Convention for the Protection of Human Rights and Dignity 
of the Human Being with Regard to the Application of Biology and 
 
 7. In this article we do not discuss preclinical research and instead focus on the three other 
subareas. 
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Medicine (also called the Oviedo Convention),8 and the EU’s Clinical 
Trials Regulation.9 
The Oviedo Convention is a treaty that has been ratified by three of 
the states included in the study: France, Spain, and Switzerland. There-
fore, the provisions of the Oviedo Convention are officially binding on 
these states. According to the treaty provisions, research on, and in vitro 
modification of, IVF embryos is permitted, but the creation of research 
embryos is prohibited.10 In addition, interventions “seeking to modify the 
human genome” must have “preventive, diagnostic or therapeutic pur-
poses” and not “introduce any modification in the genome of any de-
scendants.”11 In this article, we limit our analysis to the ratification status 
of the Oviedo Convention in the states that are members of the Council 
of Europe, but do not discuss its provisions. 
The EU Clinical Trials Regulation, set to take effect in late 2021, 
bans all 27 EU member states from conducting gene therapy trials that 
can result in modifications to the research subject’s germline.12 This 
means that no EU member state will be able to authorize clinical trials in 
which genetic modification technologies are tested on humans. Since 
what remains uncertain is when it will become applicable not if, the syn-
opses refer to this Regulation assuming it is already effective.13 
 
 8. Convention for the Protection of Human Rights and Dignity of the Human Being with 
regard to the Application of Biology and Medicine [Oviedo Convention], Apr. 4, 1997, ETS no. 
164 (entered into force Dec. 1, 1999). 
 9. Regulation (EU) No 536/2014 of the European Parliament of 16 April 2014 on Clinical 
Trials on Medicinal Products for Human Use and Repealing Directive 2001/20/EC, 2014 O.J. (L 
158) 1, 158 [hereinafter Regulation (EU) 536/2014]. Both instruments are discussed at length in 
Cesare P. R. Romano, Andrea Boggio & Jessica Almqvist, The Governance of Human (Germline) 
Genome Modification at the International and Transnational Levels, in HUMAN GERMLINE 
GENOME MODIFICATION AND THE RIGHT TO SCIENCE 22, 31; Jessica Almqvist & Cesare P.R. Ro-
mano, The Regulation of Human Germline Genome Modification in Europe, in HUMAN GERMLINE 
GENOME MODIFICATION AND THE RIGHT TO SCIENCE 155, 193-97. 
 10. Oviedo Convention, supra note 8, art. 18. 
 11. Id. art. 13. 
 12. The European law currently in effect already prohibits such clinical trials. However, the 
European law is in the form of a directive, which means member states have some flexibility in 
implementing it. The regulations remove that flexibility. See Council Directive 2001/20/EC of the 
European Parliament and Council of 4 April 2001 on the Approximation of the Laws, Regulations 
and Administrative Provisions of the Member States Relating to the Implementation of Good Clin-
ical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use, 2001 O.J. (L 
121) 34 [hereinafter Council Directive 2001/20/EC]. 
 13. Likely they will become effective in late 2020 as soon as the audit of the new clinical trials 
portal and database is completed. See Clinical Trial Regulation, EUR. MEDS. AGENCY, https://
www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/clinical-trial-regu-
lation (last visited Feb 16, 2020). 
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II. NATIONAL FRAMEWORK SYNOPSES 
A.  Australia 
In Australia, key statutes regulating research on embryos and clini-
cal trials were adopted in the early 2000s and, for the most part, have been 
left untouched since then.14 The statutory law and associated guidelines 
create “a highly restrictive regime”15 revolving around the prohibition to 
create research embryos, with “embryo” being defined broadly.16 Re-
search on supernumerary embryos and gametes, including their modifi-
cation, is permissible provided the goals of the research are therapeutic 
and cannot be achieved without using embryos.17 Gametes cannot be used 
to create embryos for either research or reproductive purposes.18 Further, 
applying germline modifications is considered a criminal offense when 
“the genome of a human cell [is altered] in such a way that the alteration 
is heritable by descendants of the human whose cell was altered.”19 The 
prohibition seems to also extend logically to clinical research because, if 
undertaken, this research would involve a genome alteration that is able 
to be passed on “to future generations.”20 The prohibition, however, is not 
explicit and, as Nicol points out, “[t]he extent to which [the] prohibition 
[of Section 15] might apply in the research context awaits definitive stat-
utory interpretation.”21 
 
 14. Prohibition of Human Cloning for Reproduction Act 2002 (Cth) 24 n.3 (Austl.); Research 
Involving Human Embryos Act 2002 (Cth) 48 nn.3-4 (Austl.). 
 15. Dianne Nicol, The Regulation of Human Germline Genome Modification in Australia, in 
HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE 543, 560. 
 16. See Prohibition of Human Cloning for Reproduction Act 2002 (Cth) s 8 (Austl.); Research 
Involving Human Embryos Act 2002 (Cth) s 7 (Austl.) (an embryo is “a discrete entity that has 
arisen from either: (a) the first mitotic division when fertilisation of a human oocyte by a human 
sperm is complete; or (b) any other process that initiates organised development of a biological 
entity with a human nuclear genome or altered human nuclear genome that has the potential to 
develop up to, or beyond, the stage at which the primitive streak appears; and has not yet reached 
8 weeks of development since the first mitotic division”). 
 17. NAT’L HEALTH AND MED. RSCH. COUNCIL, ETHICAL GUIDELINES ON THE USE OF 
ASSISTED REPRODUCTIVE TECHNOLOGY IN CLINICAL PRACTICE AND RESEARCH 100 (2017). 
 18. The latter falls under the general prohibition of clinical applications involving germline 
modifications. 
 19. Prohibition of Human Cloning for Reproduction Act 2002 (Cth) s 15 (Austl.). The key-
word here is “heritable,” which the explanatory memorandum of the law defines as “able to be 
passed on to subsequent generations of humans.” Explanatory Memorandum, Prohibition of Human 
Cloning for Reproduction and the Regulation of Human Embryo Research Amendment Bill 2006 
(Cth) cl 15 (Austl.). 
 20. Id. 
 21. Nicol, supra note 15, at 556 (discussing some limited circumstances where research in-
volving genetic manipulation of embryos might be allowed in Australia). 
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B.  Belgium 
Belgium has one of the most liberal regulatory frameworks of 
germline modification among European nations. It has not ratified the 
Oviedo Convention because it does not accept the limitations the treaty 
imposes on human genome modification research. The two essential stat-
utes are the 2003 Law regarding Research on Embryos In Vitro, and the 
2007 Law regarding Medically Assisted Reproduction and the Disposi-
tion of Embryos and Gametes. An embryo is defined as “a cell or coherent 
set of cells with the ability to grow into a human being.”22 Basic research 
on, and modification of, gametes and embryos, whether created for re-
search purposes or supernumerary, are lawful, yet research embryos can 
be used only if supernumerary embryos are not suitable for that research 
project.23 The research must have a therapeutic goal.24 The statute pur-
portedly allows clinical research on the transfer of modified embryos in 
humans for the purpose of testing gene therapy that benefits the specific 
embryo.25 The same provision also opens the door to clinical applications 
in the form of gene therapy that is beneficial to the embryo. Even so, the 
EU Clinical Trials Regulation prohibits this type of clinical research by 
virtue of Belgium’s membership in the EU. In the absence of the permis-
sion to run clinical trials, this gene therapy would have to be approved 
outside of Europe first, and then commercialized in Belgium, which may 
not be legally possible.26 The 1998 EU Directive on the legal protection 
of biotechnological inventions excludes the patentability of “processes 
for modifying the germ line genetic identity of human beings.”27 
C. Canada 
Canada’s regulatory framework of human genome modification is 
generally conservative. The key statute is the 2004 Assisted Human Re-
production Act, which applies throughout the federation, and defines an 
embryo as “a human organism during the first 56 days of its development 
following fertilization or creation, excluding any time during which its 
 
 22. Loi du 11 mai 2005 relative à la recherche sur les embryons in vitro [Law concerning the 
investigation on embryos in vitro] (Belg.), M.B., May 28, 2003, http://www.staatsblad.be [herein-
after In Vitro Embryo Research Law of May 11, 2003 (Belg.)]. 
 23. Id. art. 4. 
 24. Id. art. 3 (the aim must be “advancing knowledge about fertility, infertility, organ or tissue 
transplants, the prevention or treatment of diseases”). 
 25. Id. art. 5 (providing an exception to the prohibition on implantation research when “the 
research was carried out with a therapeutic goal for the embryo itself”). 
 26. Regulation (EU) 536/2014, supra note 9, art. 90. 
 27. Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the 
Legal Protection of Biotechnological Inventions, art. 6, 1998 O.J. (L 213) 13, 18. 
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development has been suspended, and includes any cell derived from 
such an organism that is used for the purpose of creating a human be-
ing.”28 According to the statute, creating research embryos is a crime,29 
and only supernumerary embryos can be used and modified in basic re-
search. This research must be carried out pursuant to the requirements set 
in the Tri-Council Policy Statement, “Ethical Conduct for Research In-
volving Humans,” a set of guidelines adopted by the national granting 
councils.30 The statement provides that the research must “benefit the em-
bryo”31 (without further specification of what “benefit” means) and that 
“embryos exposed to manipulations not directed specifically to their on-
going normal development will not be transferred for continuing preg-
nancy.”32 This seems to prohibit both clinical trials and clinical applica-
tions. Further support of this conclusion comes from the 2004 Assisted 
Human Reproduction Act, which prohibits altering “the genome of a cell 
of a human being or in vitro embryo such that the alteration is capable of 
being transmitted to descendants.”33 The statutory language does not ex-
pressly mention clinical research and the ambiguity has yet to be clarified. 
Meanwhile, no basic research using human germline modification in hu-
man embryos is being carried out in Canada.34 
D.  People’s Republic of China 
The People’s Republic of China’s (China) regulatory framework is 
under much scrutiny in the aftermath of the He Jianku affair. Its legal 
system is based on the civil law tradition, with the Communist Party hold-
ing supreme political authority. The crucial legal instruments around 
HGGM were enacted in the 2000s, although the regulation of research on 
human subjects was substantially reformed in 2016.35 Neither embryo, 
 
 28. Assisted Reproduction Act, S.C. 2004, c 2 (Can.) [hereinafter Assisted Reproduction Act 
(Can.)]. 
 29. Id. art. 5(1)(b). 
 30. CANADIAN INSTS. OF HEALTH RSCH., NAT. SCIS. AND ENG’G RSCH. COUNCIL OF 
CANADA, & SOC. SCIS. AND HUMANS. RSCH. COUNCIL OF CANADA, TRI-COUNCIL POLICY 
STATEMENT: ETHICAL CONDUCT FOR RESEARCH INVOLVING HUMANS (2014), https://www. 
cmcc.ca/Tri-Council%20Policy%20Statement.pdf. 
 31. Assisted Reproduction Act art. 12.7(a) (Can.). The statute does not define the term “ben-
efit.” 
 32. Id. art. 12.8(c). 
 33. Id. 
 34. Erika Kleiderman, The Regulation of Human Germline Genome Modification in Canada, 
in HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE83, 84. 
 35. Ren Peitai Ganxibao Yanjiu Lunli Zhidao Yuanze (人胚胎干细胞研究伦理指导原则) 
[Guiding Ethical Principles for Human Embryonic Stem Cell Research] (promulgated by the Min-
istry of Sci. and Tech. and Ministry of Health, Dec. 24, 2003), http://www.most.gov.cn/fggw/zfwj/
zfwj2003/200512/t20051214_54948.htm (China); Renlei Fuzhu Shengzhi Jishuguifan (人类辅助
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zygote, nor gamete are expressly defined. Overall, Chinese law is permis-
sive. Scientists can create research embryos (also with modified gametes) 
and use supernumerary embryos, but with government oversight.36 Re-
garding clinical research, the key regulation only limits research on so-
matic cells and does not address germline cells.37 However, the Chinese 
regulatory framework rejects, in clear terms, clinical applications of 
germline modifications. Per the Technical Norms on Assisted Reproduc-
tion, “gene manipulation of human gametes, zygotes or embryos for re-
productive purposes” is prohibited.38 Further, the Guiding Ethical Princi-
ples for Human Embryonic Stem Cell Research prohibit the implantation 
of embryos that were used for research.39 Clinical research is logically 
 
生殖技术规范) [Technical Norms on Assisted Reproduction] (promulgated by the Ministry of 
Health, May 14, 2001, rev’d by the Ministry of Health, Oct. 1, 2003), http://www.nhc.gov.cn/bgt/
pw10303/200708/68ba58984aba4a44a3bcf74b0c3e2048.shtml (China); Yiliao Jishu 
Linchuangyingyong Guanlibanfa (医疗技术临床应用管理办法) [Administrative Measures for 
the Clinical Application of Medical Technology] (promulgated by the Ministry of Health, Mar. 2, 
2009), http://www.gov.cn/gongbao/content/2009/content_1388686.htm (China); Ganxibao Zhiji 
Zhiliang Kongzhi Ji Linchuang Qian Yanjiu Zhidao Yuanze (Shixing) (干细胞制剂质量控制及
临床前研究指导原则(试行)) [Guiding Principles for Human Gene Therapy Research and Quality 
Control of Preparation (Trial)] (promulgated by Ministry of Health, Mar. 20, 2003) (China); Sheji 
Ren de Shengwu Yixue Yanjiu Lunli Shencha Banfa (涉及人的生物医学研究伦理审查办法) 
[Ethical Review Guidelines on Biomedical Research Involving Human Subjects] (promulgated by 
Nat’l Health and Family Planning Comm., Oct. 12, 2016, effective Dec. 1, 2016), http://www.nhc.
gov.cn/fzs/s3576/201610/84b33b81d8e747eaaf048f68b174f829.shtml (China). 
 36. An administrative license issued by the Human Genetic Resources Management Office is 
needed for the collection, storage, and export of human genetic materials. See Renlei Yichuan Zi-
yuan Guanli Zanxing Banfa (人类遗传资源管理暂行办法) [Interim Administrative Measures for 
Human Genetic Resources] (promulgated by the Ministry of Sci. and Tech., June 10, 1998), http://
www.most.gov.cn/fggw/xzfg/200811/t20081106_64877.htm, cl. 3, 7 (China). 
 37. Guiding Principles for Human Gene Therapy Research and Quality Control of Preparation 
(China). When this article was in production, the Chinese Criminal Code was amended to prohibit 
the implantation of genetically edited or cloned human embryos into human or animal bodies, or 
the implantation of genetically edited or cloned animal embryos into human bodies.” See Shao 
Bowen, Can China’s New Criminal Law Deter the Next He Jiankui?, SIXTH TONE (Mar. 12, 2021), 
https://www.sixthtone.com/news/1006904/can-chinas-new-criminal-law-deter-the-next-he-
jiankui. 
 38. Technical Norms on Assisted Reproduction (China), pt. III, para. 9. The same rule is also 
stated in the Ethical Principles for Human Assisted Reproductive Technology and Human Sperm 
Bank. Renlei Fuzhu Shengzhi Jishu he Renlei Jingziku Lunli Yuanze (人类辅助生殖技术和人类
精子库伦理原则) [Ethical Principles for Human Assisted Reproductive Technology and Human 
Sperm Bank] (promulgated by the Ministry of Health, May 14, 2001, rev’d by the Ministry of 
Health, Oct. 1, 2003), http://www.nhc.gov.cn/bgt/pw10303/200708/68ba58984aba4a44a3bcf74
b0c3e2048.shtml (China). Lingquiao Song & Rosario Isasi, The Regulation of Human Germline 
Genome Modification in the People’s Republic of China, in HUMAN GERMLINE GENOME 
MODIFICATION AND THE RIGHT TO SCIENCE 83, 84. 
 39. Ethical Guiding Principles on Human Embryonic Stem Cell Research (China) art. 6 (“(1) 
blastocysts obtained by in vitro fertilization, somatic cell nuclear transplantation, single-sex repli-
cation technology or genetic modification shall not be cultured for more than 14 d after fertilization 
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impossible if edited embryos cannot be implanted.40 Notably, a court 
found He Jianku’s actions were in violation of Chinese criminal law.41 
E.  France 
By ratifying the Oviedo Convention in 2011, France adopted a 
highly restrictive regulatory framework. The chief statute is the Public 
Health Code, which was amended between 1988 and 1994 to include pro-
visions on research on embryos and assisted reproduction.42 The Public 
Health Code, which does not define “embryo,” prohibits creating re-
search embryos43 but permits research on supernumerary embryos, which 
can be modified.44 Research must be reviewed and approved by the Bio-
medicine Agency (Agence de la Biomédecine), a public body set by the 
Bioethics Law.45 Among the requirements for approval are a showing that 
the study cannot be done without using embryos and that it has a medical 
aim and medical relevance.46 Research on gametes, including their mod-
ification, is not expressly regulated, which means that it is not prohibited. 
Conversely, clinical applications of germline engineering are prohibited 
by the Civil Code and the Public Health Code.47 Germline applications 
 
or transplantation; (2) the human blastocyst for research shall not be implanted into the reproductive 
system of a human or any other animal.”). 
 40. Jing-Ru Li et al., Experiments That Led to the First Gene-Edited Babies: The Ethical 
Failings and the Urgent Need For Better Governance, 20 J. ZHEJIANG UNIV. SCI. B., 32, 32–37 
(2019). (pointing out that He Jianku’s research was not properly approved by an Ethics Committee. 
He Jianku only received approval from the Ethics Committee of the Shenzhen HarMoniCare 
Women and Children’s Hospital, which was not a registered committee and therefore without the 
authority to approve the research protocol). 
 41. Antonio Regalado, He Jiankui Faces Three Years in Prison for CRISPR Babies, MIT 
TECH. REV., (Dec. 30, 2019), https://www.technologyreview.com/s/614997/he-jiankui-sentenced-
to-three-years-in-prison-for-crispr-babies/ (discussing He Jianku’s criminal conviction). See also 
Henry T. Greely, CRISPR’d Babies: Human Germline Genome Editing in the “He Jiankui affair”, 
6 J. L. BIOSCIENCES 111, 166 (2019) (“He violated Chinese law by procuring assisted reproduction 
for HIV carriers through recruiting uninfected men who would then provide blood for testing while 
falsely claiming to be the research subjects, that kind of fraud on an approval process should be 
actionable anywhere. The fact that the rule he allegedly circumvented may be an unjust one cannot 
here excuse his fraud.”). 
 42. Code de la santé publique [C.S.P.] [Public Health Code] art. L2151-2 (Fr.) (The relevant 
provisions were added to the Code by four laws, collectively known as “Bioethics Laws” or lois de 
bioéthique: Law No. 94–548 of July 1, 1994; Law No. 94–653 of July 29, 1994; Law No. 94–654 
of July 29, 1994; Law No. 88–1138 of December 20, 1988.). 
 43. C.S.P. art. L2151-2 (Fr.). 
 44. The modification of supernumerary embryos as part of a research protocol is not expressly 
prohibited, thus it is permissible. 
 45. C.S.P. art. L2151-5 (Fr.). 
 46. Id. 
 47. Code Civil [C. civ.] [Civil Code] art.16-4 (Fr.) (prohibiting any activity that could damage 
the integrity of the human species); C.S.P. art. L2151-5 (Fr.) (“Embryos on which research was 
carried on cannot be transferred [in the uterus] with the goal of starting a pregnancy.”). 
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may also be contrary to criminal laws against eugenic practices.48 Logi-
cally, this prohibition appears to extend to clinical research. The Civil 
Code, however, has an exception for clinical studies that investigate 
whether germline genome modifications can be used to prevent genetic 
disease.49 
F.  Germany 
More than 25 years ago, the Federal Republic of Germany adopted 
one of the most restrictive legal regimes in the world on germline cells. 
While Belgium has not ratified the Oviedo Convention because it deems 
it too restrictive, Germany has not done so because it deems the conven-
tion to be “too liberal,” particularly with regard to embryo research.50 The 
fundamental statute is the Embryo Protection Act, which defines an em-
bryo as a “human egg cell, fertilized and capable of developing, from the 
time of fusion of the nuclei, and further, each totipotent cell removed 
from an embryo that is assumed to be able to divide and to develop into 
an individual under the appropriate conditions for that.”51 Germline cells 
are cells “that lead directly from the fertilized egg cell to the egg and 
sperm cells of the resultant human being and also egg cells from insertion 
or penetration of the sperm cell until the completion of fertilization by 
fusion of the nuclei.”52 The law punishes basic research on modified gam-
etes,53 the creation of research embryos,54 and any “use” of embryos for 
any purpose other than their “preservation.”55 
 
 48. Code Pénal [C. pén.] [Penal Code] arts. 214-1, 214-3, 214-4 (Fr.). 
 49. C. civ. art. 16-4 (Fr.) (genetic modifications intended to alter the progeny of a person are 
prohibited with no “prejudice for research aiming at preventing or treating a genetic disease”). 
 50. Almqvist & Romano, supra note 9, at 169. 
 51. Embryonenschutzgesetz [ESchG] [The Embryo Protection Act], §§ 8.1, 8.2 (Ger.), https://
www.gesetze-im-internet.de/eschg/BJNR027460990.html. (Section 8.2 specifies that a fertilized 
egg is considered an “embryo” in the first 24 hours after the fusion of nuclei unless it is clear that 
it is not capable of developing beyond the one-cell stage). See Timo Faltus, The Regulation of 
Human Germline Genome Modification in Germany, in HUMAN GERMLINE GENOME 
MODIFICATION AND THE RIGHT TO SCIENCE 241, 252. 
 52. ESchG § 8.3 (Ger.). It is disputed whether this definition covers artificially-created gam-
etes. See Faltus, supra note 51, at 252. 
 53. ESchG § 5.4 (Ger.) (clarifying that “any use of it for fertilization has been ruled out”). 
 54. ESchG § 1.1 (Ger.). An interesting aspect of German law is the extraterritorial reach of 
the criminal provisions of the Embryo Protection Act: German-based scientists are punished even 
if the actions that are in violation of criminal law took place abroad, as part of a research collabo-
ration. See Strafgesetzbuch [StGB] [Penal Code], § 9(2), translation in https://www.gesetze-im-
internet.de/englisch_stgb/englisch_stgb.html (Ger.); Faltus, supra note 51, at 245. 
 55. ESchG § 1.1 (Ger.). Hypothetically, research that does not result in the destruction of the 
embryo is permitted. However, the law prohibits modifying the genetic characteristics of human 
germline cells and, because both clinical research and applications are prohibited, the implant of 
these embryos is punishable. Id. § 5. 
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G. Israel 
Famously hailed as “the quintessential start-up nation,”56 Israel re-
lies on a vibrant biotechnology sector. It favors innovation in all areas of 
scientific and technological research, and human genome germline mod-
ifications is no exception. The central statute is the Prohibition of Genetic 
Intervention, which was adopted in 1999 and amended several times 
since.57 The statute, which does not define what an “embryo” is, permits 
the creation of research embryos and research on supernumerary em-
bryos.58 Both can be modified but, when modified, cannot be used for 
reproductive purposes. In fact, using “reproductive cells that have under-
gone a permanent intentional genetic modification (germline gene ther-
apy) to create a person” is punishable with up to four years imprisonment 
or a fine. 59 This provision clearly prohibits clinical research and applica-
tions. Nevertheless, the prohibition against engaging in clinical research 
is not absolute: “fearing a total ban might hinder medical progress, the 
Law includes a section that allows the minister of health to permit, 
through regulations, and as an exception to the overall prohibition, the 
performance of specific kinds of genetic interventions involving the re-
productive use of germ cells that have undergone a genetic 
modification.”60 This puts Israel in the unique position of having a mech-
anism in place that would permit clinical research involving germline ge-
nome modifications without requiring legislative intervention. 
H.  Italy 
Despite not having ratified the Oviedo Convention, Italy adopted a 
restrictive legal framework. The key statute is the Medically Assisted Re-
production Law of 2004, which prohibits the creation of research em-
bryos and research on supernumerary embryos. The statute does not de-
fine the term “embryo.” The use of gametes in research, including their 
editing, is not expressly prohibited and therefore, can be considered law-
ful. These gametes cannot be used to create embryos for infertility 
 
 56. DAN SENOR & SAUL SINGER, START-UP NATION: THE STORY OF ISRAEL’S ECONOMIC 
MIRACLE (2011). 
 57. Prohibition of Genetic Intervention (Human Cloning and Genetic Manipulation of Repro-
ductive Cells) Law, 5759-1999, SH 1697 47 (1998-99), as amended (Isr.). The law was amended 
in 2004, 2009, and 2016. Vardit Ravitsky & Gali Ben-Or, The Regulation of Human Germline 
Genome Modification in Israel, in HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT 
TO SCIENCE 568SCIENCE568, 571. 
 58. Prohibition of Genetic Intervention Law (Isr.); Ravitsky and Ben-Or, supra note 57, at 
573. 
 59. Prohibition of Genetic Intervention Law (Isr.). 
 60. Ravitsky & Ben-Or, supra note 57, at 573. 
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treatment.61 On the one hand, the law permits experimenting on embryos 
by modifying them if the goal is diagnostic or therapeutic (protecting the 
health and development of the embryo), and no alternatives are availa-
ble.62 This means that basic research intended to benefit an embryo is 
lawful. On the other hand, clinical research is prohibited both by domestic 
law63 and EU law. This means that the embryos that were “treated” (i.e., 
modified in research) as part of research cannot be used in clinical trials. 
The statute also prohibits destroying embryos,64 which, since they cannot 
be implanted, are being stored sine die. By contrast, clinical applications 
involving germline modifications are not prohibited.65 However, since 
this form of gene therapy cannot be authorized in Europe, only gene ther-
apies tested and approved outside of Europe could be offered to Italian 
patients if these therapies are ever developed. 
I.  Japan 
The Japanese regulatory environment is also restrictive. The key in-
struments are the Act on Regulation of Human Cloning Techniques,66 and 
the Fundamental Policy Regarding Handling of Human Embryos,67 which 
are issued by the executive. The act defines an embryo as “a cell (except 
for a Germ Cell) or a cell group which has the potential to grow into an 
individual through the process of development in utero of a human or an 
Animal and remains at a stage prior to placental formation.”68 The policy 
prohibits creating research embryos but permits research on supernumer-
ary embryos, including modifying their genome as long as the purpose of 
the research is therapeutic.69 Research on gametes, including their ge-
nome modification, is also permitted in Japan but said research cannot be 
 
 61. Legge 19 febbraio 2004, n.40, G.U. Feb. 24, 2004, n.45 [Rules on Medically Assisted 
Procreation Act] (It.). 
 62. Id. 
 63. Decreto legislativo 24 giugno 2003, n.211, G.U. Aug. 9, 2003, n.184 (It.) (implementing 
Council Directive 2001/20/EC). 
 64. L. n. 40/2004 (It.). 
 65. Ludovica Poli, The Regulation of Human Germline Genome Modification in Italy, in 
HUMAN GERMLINE MODIFICATION AND THE RIGHT TO SCIENCE 335, 355–56. 
 66. Hito ni kansuru kurōn gijutsu-tō no kisei ni kansuru hōritsu [Act on Regulation of Human 
Cloning Techniques Act], Law No. 146 of 2000, art. 1(i) (Japan). 
 67. Sōgō kagaku gijutsu kaigi [Council for Science and Technology Policy], Hito hai no tori-
atsukai ni kansuru kihon-teki kangaekata [Fundamental Policy Regarding Handling of Human 
Embryos] (July 23, 2004), https://www8.cao.go.jp/cstp/tyousakai/life/haihu39/siryo5-1-1.pdf (Ja-
pan). 
 68. Act on Regulation of Human Cloning Techniques Act, art. 2 (Japan). 
 69. Fundamental Policy Regarding Handling of Human Embryos, supra note 67, art. 9.2 (im-
plying that research embryos can only be used in in vitro experiments to study a disease). 
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used to create an embryo.70 Although, the policy does prohibit clinical 
research to develop “gene therapy” using germline genome editing. The 
definition of “gene therapy” (“the administration of a gene or cells into 
which a gene was transferred for the purposes of treatment and prohibi-
tion of a disease”) creates a loophole.71 According to Ishii, clinical re-
search that uses only nucleases in the form of mRNA or protein to cause 
the germline modification does not constitute germline cell “gene ther-
apy,” and thus is not prohibited.72 However, ministerial guidelines ban 
clinical applications and is a further obstacle to clinical research because 
they prohibit the transfer of modified embryos to a uterus.73 
J.  Republic of Korea 
The Republic of Korea (South Korea) is, besides Israel, one of the 
states that invests the most in research and investment. However, when it 
comes to HGGM, South Korea has a conservative regulatory framework. 
The key statute—the Bioethics and Safety Act, which was adopted in 
2005 and then revised in 2008, 2012, and 2015—defines an embryo as “a 
fertilized human ovum or a group of [segmented] cells divided during a 
period from the time such ovum is fertilized until the time all organs are 
embryologically formed.”74 The statute prohibits and criminally sanctions 
the creation of research embryos,75 but permits research and modification 
of supernumerary embryos and gametes.76 Research must have a thera-
peutic focus or be otherwise approved by the President upon review of 
the National Bioethics Committee.77 
 
 70. Ministry of Education, Culture, Sports, Science and Technology [MEXT], Hito iPS saibō 
matawa hito soshiki kan saibō kara no seishoku saibō no sakusei o okonau kenkyū ni kansuru 
shishin [Guidelines on Research into Producing Germ Cells from Human Induced Pluripotent Stem 
Cells or Human Tissue Stem Cells], MEXT Public Notice No. 88 of 2010, art. 6, translated in 
MEXT’s online database, https://www.lifescience.mext.go.jp/files/pdf/n1567_02r2.pdf (Japan). 
 71. Tetsuya Ishii, The Regulation of Human Germline Genome Modification in Japan, in 
HUMAN GERMLINE MODIFICATION AND THE RIGHT TO SCIENCE 441, 459 (quoting article 2.1 of 
the Ministry of Health, Labor and Welfare [MHLW], Idenshi chiryō-tō rinshō kenkyū ni kansuru 
shishin [Guidelines for Clinical Research Such as Gene Therapy] (Aug. 27, 2015), MHLW Noti-
fication No. 344 (Japan)). 
 72. Id. at 460. 
 73. MEXT, Tokutei hai no toriatsukai ni kansuru shishin [Guidelines on the Handling of Spec-
ified Embryos], MEXT Public Notice No. 83 of 2009, art. 7, https://www.lifescience.mext.go
.jp/files/pdf/30_82.pdf (Japan). (“For the time being, specified embryos not prescribed in the pro-
visions of Article 3 of the Act may not be transferred to human or animal uterus.”). 
 74. Bioethics and Safety Act, amended by Act No. 12844, Nov. 19, 2014 (S. Kor.), translated 
in Korea Legislation Research Institute’s online database, https://elaw.klri.re.kr/eng_mobile/
viewer.do?hseq=33442&type=part&key=36. 
 75. Id. art. 23. 
 76. Id. art. 29. 
 77. Id. 
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The use of either embryos or gametes for reproductive purposes is 
prohibited. This is because the statute expressly prohibits “gene therapy” 
applied to human embryos, ovum, sperm, or fetuses.78 The letter of the 
law makes it clear that any treatment involving editing intervention of 
germline cells would be classified as “gene therapy.”79 A plain reading of 
the same statute leads to the conclusion that clinical trials on human 
germline genome modification are prohibited even if the statute that reg-
ulates clinical trials (the Pharmaceutical Affairs Act) does not expressly 
prohibit these types of studies.80 If embryos cannot be implanted, then 
clinical trials cannot be carried out. Ultimately, as Kim and Joly point 
out, “a degree of confusion about research studies on human germline 
genome modification” remains.81 
K.  Mexico 
Mexico’s relevant statute is a federal law—the 2008 General Health 
Law.82 The statute defines germline cells as “male and female reproduc-
tive cells that are capable of giving origin to an embryo” and an embryo 
as “the product of conception from the moment of it, and until the end of 
the twelfth gestational week.”83 “Conception” is not defined, so it is un-
clear whether embryos created in vitro fall under the scope of the statute.84 
Many of the 32 states of Mexico have enacted restrictive legislation.85 
Eighteen have constitutions protecting life from “conception.”86 Donation 
of eggs and sperm is prohibited for any purpose, including research, but 
 
 78. Id. art. 47. 
 79. Id. art. 2 (defining gene therapy as “a series of procedures to alter genes in the body for 
the purpose of preventing or treating a disease or to transfer hereditary substances or cells to which 
hereditary substances are introduced to the body”). Interestingly, the definition of gene therapy of 
the Regulation on Review and Authorization of Biological Products differs, the major difference 
being that gene therapy is defined as a product rather than a practice. See Hannah Kim & Yann 
Joly, The Regulation of Human Germline Genome Modification in the Republic of Korea, in 
HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE 500SCIENCE500, 507. 
 80. Bioethics and Safety Act (S. Kor.); Pharmaceutical Affairs Act, amended by Act. No. 
11690, March 23, 2013, art. 34(5) (S. Kor.), translated in Korea Legal Research Institute’s online 
database, https://elaw.klri.re.kr/eng_service/lawView.do?hseq=40196&lang=ENG. 
 81. Kim & Joly, supra note 79, at 508 (giving the example that purely enhancement-oriented 
research may not be prohibited). 
 82. Ley General de Salud [LGS], Diario Oficial de la Federación [DOF] 07-02-1984, 19-02-
2021 (Mex.) (Mexico lacks specific legislation regulating assisted reproductive technology and ge-
netic engineering). 
 83. LGS, art. 314 (Mex.). 
 84. María de Jesús & Medina Arellano, The Regulation of Human Germline Genome Modifi-
cation in Mexico, in HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE 
129, 137. 
 85. Id. at 142. 
 86. Id. 
TECH_TO_EIC 4/12/21  7:58 AM 
2020] The Regulation of HGGM at the National Level 215 
gametes collected for IVF and no longer needed for reproductive uses, 
can be researched.87 Research embryos cannot be created because ferti-
lizing eggs for purposes other than reproduction is a crime.88 By contrast, 
research on embryos created for reproductive purposes, including their 
modifications, can be carried out legally if the goal is therapeutic.89 
Whether these embryos can be implanted is unclear. Clinical research is 
not expressly prohibited and may be lawful when intended to benefit the 
embryo.90 The same may be true also for clinical applications. This con-
clusion is reinforced by Mexico’s handling of a mitochondrial replace-
ment procedure that took place in 2016 at a fertility center authorized by 
the federal drug regulatory agency. In the aftermath of the procedure, the 
government reviewed the events and concluded that, although not ex-
pressly allowed by the law, carrying out the procedure was not in viola-
tion of federal law.91 
L.  Netherlands 
The Netherlands, which signed but never ratified the Oviedo Con-
vention, adopted its key statute—the Embryo Act—in 2002.92 An embryo 
is defined as a “cell or coherent whole of cells with the capacity to grow 
into a human being.”93 The statute prohibits the creation of research em-
bryos,94 but permits research on gametes and on supernumerary embryos 
 
 87. LGS, art. 330 (Mex.). 
 88. Código Penal Federal [CPF], art. 154, Diario Oficial de la Federación [DOF] 14-08-1931, 
24-01-2020 (Mex.). In the study conducted by Munne and his colleagues, embryos were created 
(in vivo) for research purposes. The study was approved by the state authorities. See Santiago 
Munné, First PGT-A Using Human In Vivo Blastocysts Recovered by Uterine Lavage, 35 HUM. 
REPROD. 70, 70-80 (2020). 
 89. Reglamento de la Ley General de Salud en Materia de Investigación para la Salud 
[RLGSMIS], art. 56, Diario Oficial de la Federación [DOF] 06-01-1987, 02-04-2014 (Mex.) (em-
bryo research is lawful if it aims to “solve sterility problems that cannot be solved in any other way, 
respecting the couple’s moral, cultural and social point of view, even if it differs from that of the 
investigator”). According to Medina Arellano, “supernumerary IVF embryos are often used for 
basic science research in private and public health research settings.” Jesús & Arellano, supra note 
84, at 148. 
 90. Id. at 151 (stating that “since genetic engineering on IVF human embryos is not prohibited 
when it is carried out for the benefit of the embryo or fetus, it could be inferred that it is permitted. 
In addition, if genetic modification of the human germline leads to a benefit to the embryo/fetus, it 
can be said that clinical application can be allowed”). 
 91. Id. at 151–152. 
 92. Chart of Signatures and Ratifications of Treaty 164, COUNCIL OF EUR., https://www.coe.
int/en/web/conventions/full-list/-/conventions/treaty/164/signatures (last visited Feb. 13, 2021); 
Wet van 20 juni 2002, Stb. 2002 (Neth.) [hereinafter Embryo Act (Neth.)]. 
 93. Embryo Act (Neth.), art. 1.c. 
 94. Id. art. 24.a. 
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that are “likely to lead to new insights in the field of medical science.”95 
Basic researchers can modify gametes and embryos, but neither can be 
implanted or used to create embryos.96 As a member of the EU, clinical 
research is prohibited.97 Clinical applications are also prohibited because 
modified gametes and embryos cannot be used for reproductive purposes; 
therefore, a pregnancy cannot be initiated using modified germline tis-
sue.98 
M.  Singapore 
With biotech expected to be a “key driver” of the future economy,99 
Singapore’s regulatory system is among the most permissive. The pri-
mary regulatory instruments are guidelines issued by the Bioethics Advi-
sory Committee, which is appointed by the executive branch of govern-
ment.100 These guidelines define an embryo as “the beginning of an 
organism in the early stages of development; a stage (between the ovum 
and the foetus) in the prenatal development of a mammal.”101 According 
to these guidelines, basic scientists can create research embryos or use 
supernumerary embryos, and then can modify either of them in vitro.102 
The creation of research embryos is, however, authorized by the Ministry 
of Health only on a case-by-case basis, provided the research has strong 
scientific merit, shows potential therapeutic benefits, and there is no ac-
ceptable alternative.103 Clinical research involving genome-editing tech-
niques is considered to be research into “medicinal products” as defined 
by the Medicines Act,104 and is prohibited. While not prohibited by stat-
ute, in 2005 the Bioethics Advisory Committee adopted an advisory opin-
ion that imposed a moratorium on therapeutic applications and, conse-
quently, research of germline genetic modification.105 In 2014, the 
Bioethics Advisory Committee appointed a Germline Modification 
 
 95. Id. at 10.a, 10.b; Wet van 26 Februari 1998, Stb. 1998, arts. 14.1, 16 (Neth.). 
 96. Embryo Act (Neth.), art. 24.g (prohibiting “deliberately modifying the genetic material of 
the nucleus of human germ cells with which a pregnancy will be established”). 
 97. Regulation (EU) 536/2014, supra note 9, art. 90. 
 98. Embryo Act (Neth.), art. 24.g. 
 99. Linette Lai, Biotech Expected to be Key Driver of Future Economy, STRAITS TIMES 
(2018), https://www.straitstimes.com/singapore/biotech-expected-to-be-key-driver-of-future-eco
nomy (last visited Feb 13, 2020). 
 100. BIOETHICS ADVISORY COMM., ETHICAL, LEGAL AND SOCIAL ISSUES IN HUMAN STEM 
CELL RESEARCH, REPRODUCTIVE AND THERAPEUTIC CLONING (2002) (Sing.). 
 101. Id. at Glossary-2. 
 102. Id. at 3. 
 103. Id. at 30 
 104. Medicines Act, 1975, c. 176, § 3 (Sing.), https://sso.agc.gov.sg/Act/MA1975. 
 105. BIOETHICS ADVISORY COMM., supra note 100, at 10. 
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Working Group to review the status quo. To date, no recommendation 
has been adopted.106 
N.  Spain 
In 2000, Spain ratified the Oviedo Convention, which was incorpo-
rated into Spanish law, and in 2007 it adopted its key statute, the Biomed-
ical Research Law. The Biomedical Research Law adopts the unusual 
distinction between embryos and pre-embryos.107 The embryo is “a ferti-
lized oocyte [that] is found in the uterus of a woman” up to 56 days of 
development. A pre-embryo is a group of cells that is in vitro and “the 
result of the progressive division of the oocyte from the time it is ferti-
lized until 14 days after.” From the standpoint of comparative legal anal-
ysis (and science), pre-embryos are, to all effects, embryos, and we will 
treat them as such in this part. With this caveat in mind, Spanish law per-
mits gamete research and modification provided they are not used for re-
productive purposes.108 The creation of research embryos is prohibited,109 
but research on supernumerary embryos is permitted with less restrictions 
in terms of scope of inquiry.110 These embryos, however, cannot be im-
planted.111 By contrast, a different provision of the law permits therapeu-
tic interventions on embryos.112 This is not research, as the title of the law 
indicates, but gene therapy. This gene therapy does not extend to genome 
modifications because the genome of these embryos cannot be modi-
fied.113 The law is silent about implanting these embryos in the uterus 
after the interventions. yet logically they must be implanted, or the pur-
pose of the intervention would be moot. It is permissible to perform clin-
ical research by monitoring the embryos in the uterus that underwent ther-
apy, but again the embryos’ genomes must have not been modified.114 
 
 106. Calvin W. L. Ho, The Regulation of Human Germline Genome Modification in Singapore, 
in HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE, 516, 524. 
 107. See Cinzia Piciocchi & Lucia Martinelli, The Change of Definitions in a Multidisciplinary 
Landscape: The Case of Human Embryo and Pre-embryo Identification, 57 CROATIAN MED. J. 
510, 515 (2016) (discussing the distinction). 
 108. B.O.E. 2006, 14, art. 14 (Spain). 
 109. B.O.E. 2007, 159, preamble (Spain). 
 110. B.O.E. 2006, 14, art. 13 (Spain). Researchers can modify embryos and investigate thera-
peutic and nontherapeutic aspects. 
 111. B.O.E. 2006, 14, art. 14 (Spain). 
 112. Id. (“Interventions must treat pathologies with a precise diagnosis, with a serious or very 
serious prognosis, and that offer reasonable possibilities of improvement or cure.”). 
 113. Id. (Requiring that “non-pathological hereditary characteristics are not modified and that 
the selection of individuals or race is not sought”). This is a clinical application but not germline 
modification. 
 114. B.O.E. 2015, 1090, art. 17.3 (Spain). (“Clinical trials with gene therapy medicinal prod-
ucts that cause changes in the gene identity of the person’s germline are prohibited.”). They are 
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Clinical applications of germline modifications are expressly prohib-
ited.115 
O.  Sweden 
Sweden, which has not ratified the Oviedo Convention, has a regu-
latory framework more liberal than many other European states. Basic 
research involving germline modifications can be carried out on gametes, 
supernumerary embryos, and research embryos. Key terms, like embryo 
or gamete, are not defined. Clinical research is prohibited both by the EU 
Clinical Trials Regulation and the Genetic Integrity Act—the latter of 
which is the leading statute in Sweden in the area of gene editing.116 The 
same statute classifies clinical applications of germline engineering as 
“gene therapy” and prohibits them.117 The two prohibitions are triggered 
when germline modifications “that can be inherited” (clinical trials) or 
that “are intended to bring about genetic changes that can be inherited” 
(clinical applications).118 The language in the two provisions differ in that 
“intent” is only required in the latter case. The definition of “gene ther-
apy” also assumes that the patient is affected by a “genetic disease.” A 
plain reading of the statute seems to exclude nontherapeutic interven-
tions—those purely aimed at enhancement—from the scope of the prohi-
bition. There is also a general prohibition to implant gametes and ferti-
lized eggs that have been used in research.119 In 2017, the Swedish 
National Council on Medical Ethics recommended revision of the law in 
light of the latest scientific developments,120 but no revision has been 
made to date. 
 
also prohibited as a matter of EU Regulation on Clinical Trials. B.O.E. 2007, 159, art. 74 (Spain). 
(punishing the “carrying out of any intervention aimed at the introduction of a modification in the 
genome of the descent”). 
 115. For a more liberal interpretation of Spanish law, see Iñigo de Miguel Beriain & Carlos 
María Romeo Casabona, The Regulation of Human Germline Genome Modification in Spain, in 
HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE 358, 375 (“[W]e believe 
that in Spain basic and clinical research using germline modification technologies and clinical ap-
plication of these techniques are legal as long as they do not involve the introduction of new genetic 
material into the human genome, nor intend to change the human genome (even if they cause this 
final effect).”) (emphasis added). 
 116. 3-5 § LAG OM GENETISK INTEGRITET M.M (Svensk fӧrfattningssamling [SFS] 2006:351) 
(Swed.). (“Experiments for the purposes of research or treatment that entail genetic changes that 
can be inherited in humans may not be carried out.”). 
 117. Id. (“Treatment methods that are intended to bring about genetic changes that can be in-
herited in humans may not be used.”). 
 118. Id. 
 119. Id. 
 120. Tillsӓtt en Parlamentarisk Utredning för att se över Lagstifningen på Genteknikområdet 
[Letter on the Study of Legislation for New Genetic Engineering], Swedish National Council on 
Medical Ethics (Jun. 7, 2018) (Switz.). 
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P.  Switzerland 
The regulatory approach of Switzerland, which has ratified the 
Oviedo Convention in 2008, is restrictive, starting from the Federal Con-
stitution protecting human beings “against the misuse of reproductive 
medicine and gene technology.”121 The relevant statutes provide the fol-
lowing definitions: germline cells are defined as “reproductive cells (in-
cluding their precursor cells), impregnated ova and embryonic cells 
whose genetic material can be passed on to offspring;”122 an embryo is 
defined as “the developing offspring from the time of pronuclear fusion 
until the end of organogenesis”;123 and a surplus embryo is defined as “an 
embryo produced in the course of an in vitro fertilization (IVF) procedure 
that cannot be used to establish a pregnancy and therefore has no prospect 
of survival.”124 The creation of research embryos and the storage of a fer-
tilized egg or embryo—for purposes other than assisted reproduction—is 
a criminal offense.125 Intentional germline modifications are also pun-
ished criminally.126 Somewhat less severe, supernumerary embryos may 
not be used in research. Clinical research and clinical applications are 
also restricted because of the general prohibitions against both modifying 
the genetic makeup of gametes and initiating a pregnancy with an edited 
embryo or an embryo resulting from edited gametes. 
Q.  United Kingdom 
The United Kingdom’s regulatory framework is highly supportive 
of research involving germline genome modification, particularly now 
that the state is no longer bound by the EU Clinical Trials Regulations 
after Brexit.127 The main authority, the Human Fertilisation and Embry-
ology Act of 1990, provides definitions of both “embryos” and 
 
 121. BUNDESVERFASSUNG [BV], [CONSTITUTION] Apr. 18, 1999, SR 101, art. 119 
(Switz.). 
 122. BUNDESGESETZ ÜBER DIE MEDIZINISCH UNTERSTÜTZTE FORTPFLANZUNG [FEDERAL 
ACT ON MEDICALLY ASSISTED REPRODUCTION] Dec. 18, 1998, RS 810.11, art. 2 (Switz.). 
 123. Id. 
 124. BUNDESGESETZ ÜBER DIE FORSCHUNG AN EMBRYONALEN STAMMZELLEN [FEDERAL 
ACT ON RESEARCH INVOLVING EMBRYONIC STEM CELLS] Dec. 19, 2003, RS 810.31, art. 2 
(Switz.). 
 125. Federal Act on Medically Assisted Reproduction, art. 29, para. 1-2 (Switz.). 
 126. Id. (“Any person who genetically modifies a germline cell or an embryonic cell shall be 
punished with reclusion not exceeding three years or a monetary penalty. The same penalty shall 
apply to any person who uses a genetically modified reproductive cell for impregnation or uses a 
similarly modified impregnated ovum for further development into an embryo.”). 
 127. The United Kingdom is also a member of the Council of Europe but did not ratify the 
Oviedo Convention. Almqvist & Romano, The Regulation of Human Germline Genome Modifica-
tion in Europe, supra note 9, at 170. 
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“gametes.”128 Research on gametes, the creation of research embryos, and 
research on supernumerary embryos are all lawful.129 All three can further 
be modified. Clinical research is not permissible because the Human Fer-
tilisation and Embryology Authority, which supervises clinical research, 
cannot issue “therapeutic licenses.”130 Embryos can be used in basic re-
search upon the issuance of a “research license,” but this license does not 
authorize their use for treatment. That can only occur if a treatment li-
cense is issued. Currently, the Human Fertilisation and Embryology Au-
thority does not have the power to issue a treatment license, which means 
that both clinical research and applications are not permitted. However, 
the path that has led to the approval of mitochondrial donation for thera-
peutic purposes could be followed in the future.131 For that, parliamentary 
debate and legislative reform would be needed, which may well take 
place in the immediate future. 
R.  United States 
The regulatory framework of the United States is fragmented be-
cause of the limited reach of federal laws and regulations. States have the 
power to define what an embryo is and to draw the boundaries of the 
legality of basic research on gametes and embryos. Several states have 
adopted a variety of approaches to exercise this power, ranging from ban-
ning all forms of basic research to allowing the creation and modification 
of research embryos.132 Federal law plays a limited role in areas such as 
embryo research funding and clinical research. Regarding embryo re-
search funding, the so-called Dickey-Wicker Amendment of 1996 pro-
hibits using federal funds to create, destroy, or knowingly injure human 
embryos.133 Nevertheless, private or state funds (where permitted) can be 
used to create embryos, also with modified gametes, and to carry out 
basic research on them.134 Clinical research is prohibited because the gene 
therapy approval agency—the Food and Drug Administration (FDA)—
cannot accept applications for clinical trials involving modified embryos 
 
 128. Human Fertilisation and Embryology Act 1990, § 1 (Eng.). 
 129. James Lawford Davies, The Regulation of Human Germline Genome Modification in the 
United Kingdom, in HUMAN GERMLINE MODIFICATION AND THE RIGHT TO SCIENCE, 217, 226-28 
(Andrea Boggio, Cesare P.R. Romano & Jessica Almqvist eds., 2020). 
 130. Id. at 230. 
 131. Id. at 233-40. 
 132. Kerry Lynn Macintosh, The Regulation of Human Germline Genome Modification in the 
United States, in HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE, 103, 
113–115, 124 (Andrea Boggio, Cesare P.R. Romano & Jessica Almqvist eds., 2020). 
 133. Id. at 121. 
 134. Germline modification basic research can take place in various states. Id. at 122-123. 
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or embryos created using modified gametes.135 There is no formal prohi-
bition of clinical applications at the federal level,136 yet because the FDA 
cannot green-light clinical research, no FDA-approved germline clinical 
application can be offered to patients. Under the FDA, doing otherwise 
would be illegal under federal law because gene therapy must be ap-
proved prior to marketing.137 
III.  FINDINGS 
Our study reveals a highly fragmented regulatory landscape. To 
date, no state has enacted truly comprehensive legislation on gene edit-
ing. By “comprehensive legislation” we mean a regulatory framework 
that regulates all segments of the research pipeline “from bench to bed-
side” (e.g., basic research on gametes and embryos; clinical trials with 
human participants; and clinical applications of germline genome edit-
ing). Instead, many states have approached the issue in a piecemeal fash-
ion, opting to regulate individual segments. Some do not regulate all seg-
ments of the research pipeline expressly,138 or they fail to define key 
terms,139 or they use key terms inconsistently across the different seg-
ments, resulting in incoherent regulatory frameworks. Vagueness and 
ambiguity are particularly concerning, considering that violations are 
punished with heavy penalties, including criminal ones, in all the states 
included in our study. Moreover, these legal frameworks generally pre-
date 2012,140 the year Wired Magazine labeled the “Great CRISPR 
 
 135. The FDA has stated that it considers any use of CRISPR/Cas9 gene editing in humans to 
be gene therapy. U.S. Food & Drug Admin., Information About Self-Administration of Gene Ther-
apy (2017), https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/infor-
mation-about-self-administration-gene-therapy. 
 136. Macintosh, supra note 132, at 125. 
 137. Id. Interestingly, in 2019 California enacted a consumer protection statute mandating that 
gene therapy kits are sold with a label that states that they are not intended for self-administration. 
This is the first statute expressly addressing CRISPR-based applications in the United States. S.B. 
180, 2019-2020 Sess. (Cal. 2019). 
 138. The regulation of clinical trials is affected by significant gaps or vagueness in Australia, 
Canada, China, Korea, and Mexico. Mexico and Spain do not have clear rules as to whether em-
bryos that were used in research can be implanted (this is research that benefits the embryos). The 
laws of Belgium, France, and Italy, which prohibit clinical research but not clinical application, do 
not discuss under what conditions these applications can be offered to patients in the absence of a 
pathway to regulatory approval. 
 139. E.g., China, France, Israel, Italy, Sweden. In the United States, embryos and gametes are 
not defined under federal law. 
 140. On August 17, 2012, Science Magazine published a paper co-authored by a group of seven 
scientists that included Jennifer Doudna and Emmanuelle Charpentier, which is credited for fram-
ing CRISPR/Cas-9 as a gene editing tool. See Martin Jinek et al., A Programmable Dual-RNA-
Guided DNA Endonuclease in Adaptive Bacterial Immunity, 337 SCI. 816 (2012), https://www.ncbi
.nlm.nih.gov/pmc/articles/PMC6286148/pdf/nihms-995853.pdf. 
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Quake.”141 Human genome modifications are regulated with legal instru-
ments dating back to the 1990s and early 2000s. Few have updated their 
regulatory framework after 2012.142 
Overall, research on human embryos is the most heavily regulated 
subarea and has the most advanced regulations. That is unsurprising since 
artificial reproductive technologies had already taken off in the 1970s and 
the legal status of embryos has been debated for even longer. Here, na-
tional laws tend to be more precise and compelling than those regulating 
other subareas. Indeed, for each state surveyed, it is possible to say 
whether research embryos can be created, under what conditions they can 
be used in research, and/or whether IVF embryos can be used in research 
and under what conditions. 
However, other more advanced aspects of embryo research are less 
clearly regulated. For instance, it is often hard to tell whether human em-
bryos can be modified using CRISPR/Cas-9 and similar techniques, or 
whether research on human germline genome modification is permissible 
only with therapeutic or enhancement-oriented goals, an issue actively 
debated in policy conversations on germline editing. 
Research on gametes is regulated with less depth. National regula-
tory frameworks do not often discuss whether, and under what conditions, 
gametes can be used for research.143 In theory, according to the legal prin-
ciple that “what is not prohibited is allowed,” one could infer that re-
search on gametes is permitted even when it is prohibited. Making infer-
ences in such a confusing and vague legal landscape, however, is 
hazardous, especially since many statutes include criminal sanctions. 
Clinical research on modified germline tissue appears to be prohib-
ited in all states included in our study. The EU Clinical Trials Regulation 
clearly prohibits “gene therapy clinical trials … which result in modifi-
cations to the subject’s germ line genetic identity.”144 Surprisingly, this 
degree of clarity is rare. Few states expressly prohibit clinical research or 
studies. They would rather leave scientists and legal advisors to infer the 
prohibition, either from the fact that the implantation in the uterus of 
 
 141. Megan Molteni, The WIRED Guide to Crispr, WIRED (Mar. 12, 2019, 6:00 AM), https://
www.wired.com/story/wired-guide-to-crispr/. 
 142. The addition or amendment of regulatory instruments dealing with basic research on 
germline tissue, clinical trials, or application of gene therapy took place in Canada, France, Japan, 
Korea, Switzerland, and the United States. Meaningful policy debates took place in the Nether-
lands. 
 143. It is to be noted that the prohibition against creating research embryos has ramifications 
for basic research on gametes. Where creating a research embryo is prohibited, research on modi-
fied gametes must stop before fertilization. Similarly, where clinical applications are prohibited, 
modified gametes cannot be used to create embryos for reproductive purposes. 
 144. Regulation (EU) 536/2014, supra note 9, art. 1. 
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modified embryos (whether research or supernumerary embryos) is pro-
hibited, or from the fact that the use of modified gametes in fertilization 
is prohibited. The prohibition to use modified gametes and embryos to 
initiate a pregnancy makes clinical trials impossible since testing 
germline modifications requires using modified germline tissue to initiate 
a pregnancy in a research subject (particularly when embryos have 
reached the fourteenth day of embryonal development and can no longer 
by cultivated in vitro). For the sake of argument, one can object that, at 
least in theory, clinical trials testing in vivo germline modifications re-
main possible. The prohibition of clinical trials can also be inferred from 
the fact that clinical applications, such as making available germline gene 
therapy to patients, are prohibited as long as enrolling a patient in a clin-
ical trial is equated to offering a germline application to that patient. If 
the latter is prohibited, the former is also prohibited. 
Clinical applications are prohibited in several states. In states where 
they are not prohibited, HGGM is prohibited if it creates “heritable” 
traits, but it is allowed if it is “intended to” benefit the embryo or treat 
“serious conditions.”145 These undefined expressions create further uncer-
tainty.146 Take the case of “heritability,” which is at the core of many na-
tional regulations, and of ethical concerns about “hacking humanity.”147 
Gene therapies involving germline modifications must be designed so 
that the pregnancy is carried out to full term. Depending on what was 
modified and how it was modified, the newborn might, but not always, 
carry the genes in the modified form. If the newborn does, is the germline 
modification still heritable if the newborn is sterile or not interested in 
reproducing, or is the newborn condemned by disease to die before reach-
ing reproductive age? And what if the heritability of the modification was 
not intentional? Should intent matter? It definitely does where criminal 
sanctions are applied, but should it also matter where violations of 
HGGM regulations are not criminally sanctioned? 
Finally, several states require research to pursue only therapeutic 
goals.148 The requirement to pursue therapeutic goals is often worded 
broadly, without further details. In some cases, therapeutic goals are lim-
ited to treating infertility or generating knowledge about genetic 
 
 145. Erika Kleiderman et al., The ‘Serious’ Factor in Germline Modification, 45 J. MED. 
ETHICS 508, 512 (2019). 
 146. Id. at 510. 
 147. Id. at 508. 
 148. L. n. 40/2004 (It.). This is not mentioned in China, Israel, Spain, Sweden, and the United 
States. It is also not mentioned in Germany and Switzerland, but in both states basic research with 
embryos is prohibited. 
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disorders.149 That would rule out basic inquiries into enhancement-ori-
ented research. In other cases, such as the one of Belgium, enhancement-
oriented research is prohibited as a form of eugenics. There, “research or 
treatments of a eugenic nature, that is focused on selection or amplifica-
tion of non-pathological genetic characteristics of the human species” is 
prohibited.150 In a handful of states, research must pursue therapeutic 
goals, provided the beneficiary of the therapy is the embryo itself. For 
instance, in Italy, although human embryos cannot be used for research, 
if the research benefits the embryo, it is permitted.151 In Spain, interven-
tions that benefit the embryo are considered permissible gene therapy.152 
Belgium permits implanting embryos used in research that benefits the 
embryo itself.153 In Mexico, genetic engineering on IVF human embryos 
is not prohibited when it is carried out for the benefit of the embryo.154 
Further, in Italy and Spain, interventions on embryos cannot alter the ge-
nome of the embryo.155 This is not true in Belgium and is unclear in Mex-
ico.156 
Limiting research only to those instances that benefit the embryo 
researched is problematic. Besides complicating further regulations that 
are already confusing and contradictory, it causes two major practical 
problems. First, it is scientifically difficult to imagine how research could 
be beneficial to the embryo without altering its genome. Second, the log-
ical consequence of saying that research must benefit the embryo re-
searched is that it makes it unlawful to destroy it in the process of re-
searching or afterwards. If the embryo cannot be destroyed, then there are 
only two possible outcomes. The first one is that it is implanted in the 
uterus. Where this is possible, clinical applications of germline 
 
 149. See In Vitro Embryo Research Law of May 11, 2003 (Belg.) (research must have “a ther-
apeutic objective or aims to advance knowledge in matters of fertility, sterility, organ or tissue 
transplants, prevention or treatment of diseases”); C. Civ., art. 16-4 (Fr.). (“to prevent genetic dis-
ease”); Jesús & Arellano, supra note 84, at 140 (Mexico: “to solve sterility problems”); Embryo 
Act (Neth.), art. 10 (“new insights in the field of medical science”); Davies, supra note 129, at 225-
26 (the United Kingdom: where advancing the understanding of embryo development along with 
therapeutic goals are acceptable goals); see also Macintosh, supra note 132. 
 150. In Vitro Embryo Research Law of May 11, 2003 (Belg.). 
 151. Poli, supra note 65, at 350. 
 152. Beriain & Casabona, supra note 115, at 361-62. 
 153. Guido Pennings, The Regulation of Human Germline Genome Modification in Belgium, 
in HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE 266, 274 (Andrea 
Boggio, Cesare P.R. Romano & Jessica Almqvist eds., 2020). 
 154. Jesús & Arellano, supra note 84, at 140. 
 155. Poli, supra note 65, at 350; Beriain & Casabona, supra note 115, at 362. 
 156. In Vitro Embryo Research Law of May 11, 2003 (Belg.), art. 5; Jesús & Arellano, supra 
note 84, at 151. 
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modifications are lawful.157 Then, logically, clinical research should be 
lawful too, to ensure that these techniques are tested before being offered 
to patients. This might be the case in Mexico.158 If embryos that have been 
manipulated during research cannot be destroyed and cannot be trans-
ferred in the uterus, then the only option left is cryopreserving them in 
perpetuity, which is an absurdity and a waste. Overall, it seems that stat-
utory language contemplating a benefit for the embryo is, at best, difficult 
to comply with, or, at worst, meaningless. 
IV.  A WAY FORWARD 
As long as states at the leading edge of human genome modification 
research do not adopt modern and comprehensive regulatory frameworks, 
human germline genome modification will remain regulated inconsist-
ently and disjointedly, with gaps, contradictions, and uncertainties.159 
Since the advent of CRISPR, those states that have attempted reform of 
existing regulatory frameworks have simply tweaked existing frame-
works instead of overhauling them.160 This has magnified inconsistencies 
and increased the number of possible interpretations. If it was difficult 
for the legal experts who wrote the book chapters in the edited collection 
to answer some of the straightforward questions we asked, one can guess 
how perplexed scientists must be. The confusion does not work to the 
advantage of both those who would like to shield human embryos from 
manipulation and those who would like to hasten the discovery and de-
livery of germline genome editing therapies. Scientists and clinicians 
must be able to make sense of the legal frameworks within which they 
operate to carry out their work confidently and responsibly. 
In streamlining and modernizing their regulatory frameworks, na-
tional lawmakers and regulators should, at a minimum, focus on the re-
search pipeline segments that need the most attention (research with gam-
etes, genome manipulation of embryos, and clinical research) and 
improve the transparency of applicable laws and regulations. Besides the 
immediate benefit of a better national regulatory framework, reform ini-
tiatives would also have an indirect benefit: they might lead to a wider 
discussion, beyond the small circle of cognoscenti, engaging lawmakers 
and hopefully citizens on a high stakes issue. Indeed, an accusation often 
 
 157. See, e.g., In Vitro Embryo Research Law of May 11, 2003 (Belg.); B.O.E. 2007, 159, art. 
74 (Spain); Jesús & Arellano, supra note 84. 
 158. Jesús & Arellano, supra note 84, at 143-44. 
 159. HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE, supra note 2, 
at 157. 
 160. Molteni, supra note 141. 
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leveled against current regulatory approaches to the regulation of HGGM 
is that they are not the outcome of public consultations and delibera-
tions.161 Considering most legal instruments were adopted in the late 
1990s to early-to-mid 2000s, well before the advent of CRISPR, they def-
initely are not suitable to regulate research and applications of new tech-
nology, such as CRISPR. Processes of legal reform might be a twofer: 
producing modern and coherent regulatory frameworks and engaging the 
public in an important conversation. National frameworks and experi-
ences will be key in the development of international and transnational 
governance of human genome editing, but only if necessary legal reforms 
are made. 
 
 161. Sheila Jasanoff et al., Democratic Governance of Human Germline Genome Editing, 2 
CRISPR J. 266 (2019). 
